0.01
+0.005(+100.00%)
Currency In CAD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
13
First IPO Date
October 25, 2007
| Name | Title | Pay | Year Born |
| Mr. G. F. Kym Anthony | Chief Executive Officer & Vice Chairman | 361,062 | 1956 |
| Mr. Ira Levy | Interim Chief Financial Officer | 120,377 | N/A |
| Dr. Graham Burton Ph.D. | Co-Founder, Chief Scientific Officer & Director | 126,334 | N/A |
| Dr. James Nickerson Ph.D. | President and Executive Vice President of Business Development & Product Innovation | 0 | N/A |
| Mr. Drew Basek | Director of Investor Relations | 0 | N/A |
| Ms. Tracy Gillett BVSC | Director of Companion Animal & Marketing Manager | 0 | N/A |
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.